PURPOSE: To evaluate the prognostic impact of the histological expression of CD133 in renal cell carcinoma (RCC). METHODS: From 1992 to 2009, 142 consecutive patients underwent radical nephrectomy or partial nephrectomy for RCC. All cases were reviewed by a single pathologist and then subjected to analysis of the immunohistochemical expression of CD133 using tissue microarray. Several clinical and pathological variables were also evaluated. RESULTS: The median postoperative follow-up was 44 months. Of the 142 immunostained RCC specimens, 77 (54%) showed low and 65 (46%) high expression of CD133. Expression of CD133 was associated with clinical stage (P = 0.05), lymph node involvement (P = 0.03), metastatic disease (P = 0.02) and MVI (P = 0.03). Among other variables, clinical stage, necrosis and metastasis were associated with disease-specific survival (DSS) and progression-free survival (PFS) on univariate analysis. The 5-year PFS rates in patients who provided specimens with high and low expression of CD133 were 83 and 66%, respectively (P = 0.01). It was observed that the 5-year DSS for patients who provided specimens with high and low expression of CD133 was 90 and 71%, respectively (P = 0.003). Multivariate survival analysis showed that patients in the CD133 low-expression group had a higher probability of disease progression (HR 3.4, P = 0.02) and a higher probability of death from cancer (HR 2.4, P = 0.01). CONCLUSIONS: Immunohistochemical expression of CD133 had an impact on survival in patients with RCC, which shows that CD133 might be a useful tool for risk stratification. Low expression of this marker remained as an independent predictor of poor DSS and PFS.
PURPOSE: To evaluate the prognostic impact of the histological expression of CD133 in renal cell carcinoma (RCC). METHODS: From 1992 to 2009, 142 consecutive patients underwent radical nephrectomy or partial nephrectomy for RCC. All cases were reviewed by a single pathologist and then subjected to analysis of the immunohistochemical expression of CD133 using tissue microarray. Several clinical and pathological variables were also evaluated. RESULTS: The median postoperative follow-up was 44 months. Of the 142 immunostained RCC specimens, 77 (54%) showed low and 65 (46%) high expression of CD133. Expression of CD133 was associated with clinical stage (P = 0.05), lymph node involvement (P = 0.03), metastatic disease (P = 0.02) and MVI (P = 0.03). Among other variables, clinical stage, necrosis and metastasis were associated with disease-specific survival (DSS) and progression-free survival (PFS) on univariate analysis. The 5-year PFS rates in patients who provided specimens with high and low expression of CD133 were 83 and 66%, respectively (P = 0.01). It was observed that the 5-year DSS for patients who provided specimens with high and low expression of CD133 was 90 and 71%, respectively (P = 0.003). Multivariate survival analysis showed that patients in the CD133 low-expression group had a higher probability of disease progression (HR 3.4, P = 0.02) and a higher probability of death from cancer (HR 2.4, P = 0.01). CONCLUSIONS: Immunohistochemical expression of CD133 had an impact on survival in patients with RCC, which shows that CD133 might be a useful tool for risk stratification. Low expression of this marker remained as an independent predictor of poor DSS and PFS.
Authors: Tobias Klatte; David B Seligson; Jeffrey LaRochelle; Brian Shuch; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz F Kabbinavar; Allan J Pantuck; Arie S Belldegrun Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-24 Impact factor: 4.254
Authors: John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck Journal: J Natl Cancer Inst Date: 2006-09-20 Impact factor: 13.506
Authors: Ilaria Lucca; Michela de Martino; Sebastian L Hofbauer; Nura Zamani; Shahrokh F Shariat; Tobias Klatte Journal: World J Urol Date: 2015-04-17 Impact factor: 4.226
Authors: Hai Huang; Xiu-Wu Pan; Yi Huang; Dan-Feng Xu; Xin-Gang Cui; Lin Li; Yi Hong; Lu Chen; Yi Gao; Lei Yin Journal: Int J Clin Exp Med Date: 2015-07-15
Authors: Matthias May; Atiqullah Aziz; Richard Zigeuner; Thomas Chromecki; Luca Cindolo; Luigi Schips; Ottavio De Cobelli; Bernardo Rocco; Cosimo De Nunzio; Andrea Tubaro; Ioman Coman; Michael Truss; Orietta Dalpiaz; Bernd Hoschke; Christian Gilfrich; Bogdan Feciche; Anette Stoltze; Fabian Fenske; Hans-Martin Fritsche; Robert S Figenshau; Kerry Madison; Manuel Sánchez-Chapado; Maria Del Carmen Santiago Martin; Luigi Salzano; Giuseppe Lotrecchiano; Steven Joniau; Raphaela Waidelich; Christian Stief; Sabine Brookman-May Journal: World J Urol Date: 2013-04-09 Impact factor: 4.226